Cinacalcet use, by DOPPS country and cross-section

  N Ptnts Total N Wgtd %
DOPPS Country DOPPS Cross-section 7 517 1.3%
AusNZ D3(2006)
D3(2007) 14 477 2.8%
D4(2010) 63 337 18.0%
D4(2011) 66 388 16.0%
Belgium D3(2006) 14 499 3.4%
D3(2007) 16 411 5.1%
D4(2010) 47 463 10.2%
D4(2011) 39 449 8.5%
Canada D3(2006) 16 545 2.7%
D3(2007) 20 443 3.4%
D4(2010) 24 339 7.4%
D4(2011) 30 467 6.1%
France D3(2006) 70 548 12.0%
D3(2007) 87 542 15.8%
D4(2010) 49 375 12.6%
D4(2011) 74 486 15.3%
Germany D3(2006) 69 576 11.6%
D3(2007) 84 620 12.7%
D4(2010) 92 618 15.2%
D4(2011) 99 619 16.3%
Italy D3(2006) 22 520 4.3%
D3(2007) 55 540 9.3%
D4(2010) 103 557 18.1%
D4(2011) 116 585 19.3%
Japan D3(2006) 3 1,821 0.2%
D3(2007) 2 1,846 0.2%
D4(2010) 274 1,698 16.1%
D4(2011) 314 1,655 19.1%
Spain D3(2006) 57 659 8.7%
D3(2007) 70 550 12.9%
D4(2010) 178 602 31.0%
D4(2011) 199 584 35.1%
Sweden D3(2006) 46 535 8.6%
D3(2007) 70 507 13.4%
D4(2010) 101 455 21.9%
D4(2011) 124 516 23.5%
UK D3(2006) 13 438 2.4%
D3(2007) 19 347 4.1%
D4(2010) 42 369 9.6%
D4(2011) 47 462 9.4%
US D3(2006) 345 1,804 20.1%
D3(2007) 308 1,316 24.9%
D4(2010) 732 3,322 21.5%
D4(2011) 876 3,751 20.8%

Medications reported as prescribed (not necessarily taken) in previous week (D2-D3) or end of study month (D4), among all patients

Please see additional methodological information in the Data Sources and Methods section.